Type-1 angiotensin II receptor B
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Type-1 angiotensin II receptor B as ChEMBL target CHEMBL263, mapped to UniProt P29089. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Why Type-1 angiotensin II receptor B matters
Type-1 angiotensin II receptor B is reviewed as Type-1 angiotensin II receptor B (UniProt P29089); the current evidence base includes 12 approved drugs, 483 compounds, and 45 assays, with lead potency reaching pChEMBL 9.8.
Type-1 angiotensin II receptor B Sequence length is 359 aa.
Review this target as Type-1 angiotensin II receptor B, mapped to UniProt P29089. Sequence length is 359 aa.
Protein source · UniProt accession via ChEMBL component mappingDisease relevance is not yet populated for this evidence card.
This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target recordChEMBL currently tracks 12 approved drugs, 483 compounds, and 45 assays for this target. The dominant activity type is IC50. CHEMBL317343 is the current potency anchor at pChEMBL 9.8.
Use CHEMBL317343 as the tractability anchor when discussing potency (pChEMBL 9.8).
Activity source · ChEMBL 36 via Core EngineStart with the right source
Pick the first block or linked source that matches the review question in front of you.
Start with the review rationale when you need to explain why Type-1 angiotensin II receptor B matters before drilling into raw source blocks.
Jump to Review RationaleGo back to the target snapshot when you need the naming and mapping contract behind UniProt P29089, not just the summarized rationale.
Open Protein ContextUse the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL317343
|
9.8 | IC50 | — |
|
|
No preferred name
CHEMBL216061
|
9.8 | Ki | — |
|
|
No preferred name
CHEMBL411997
|
9.6 | Ki | — |
|
|
No preferred name
CHEMBL279629
|
9.5 | IC50 | — |
|
|
No preferred name
CHEMBL408403
|
9.5 | Ki | Approved |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
ANGIOTENSIN II
CHEMBL408403
|
2017 |
|
|
TELMISARTAN
CHEMBL1017
|
1998 |
|
|
IRBESARTAN
CHEMBL1513
|
1997 |
|
|
EPROSARTAN
CHEMBL813
|
1997 |
|
|
VALSARTAN
CHEMBL1069
|
1996 |
|
|
LOSARTAN POTASSIUM
CHEMBL995
|
1995 |
|
|
LOSARTAN
CHEMBL191
|
1995 |
|
|
SARALASIN
CHEMBL938
|
1982 |